Management of renal hyperparathyroidism

Area of Science:

• Nephrology
• Endocrinology
• Pathology

Background:

• Renal hyperparathyroidism (HPT) involves parathyroid gland hyperplasia, progressing from diffuse polyclonal proliferation to monoclonal nodular hyperplasia.
• This progression diminishes vitamin D and calcium-sensing receptor expression, leading to medical treatment refractoriness.
• Advanced renal HPT presents challenges in controlling hyperphosphatemia and preventing complications like adynamic bone disease.

Purpose of the Study:

• To review the histopathological and pathophysiological mechanisms of renal HPT.
• To discuss preventive strategies and treatment options for advanced renal HPT.
• To highlight the importance of early intervention and monitoring in managing renal HPT.

Main Methods:

• Review of histopathological and pathophysiological investigations, including genetic approaches.
• Analysis of treatment strategies, including vitamin D metabolites, calcitriol pulse therapy, and parathyroidectomy (PTx).
• Evaluation of diagnostic tools like ultrasonography for parathyroid volume measurement and emerging therapies such as percutaneous ethanol injection, calcimimetics, and novel phosphate binders.

Main Results:

• Progression to nodular hyperplasia makes HPT refractory to medical treatment.
• Control of hyperphosphatemia is crucial but difficult.
• Vitamin D metabolite administration with PTH monitoring is recommended for prophylaxis.
• Calcitriol pulse therapy and PTx are options for advanced HPT, with timing being critical.
• Ultrasonography aids in detecting nodular glands and guiding treatment decisions.

Conclusions:

• Preventing progression to nodular hyperplasia is essential for effective renal HPT management.
• Early intervention with vitamin D metabolites and careful monitoring can prevent advanced disease.
• Surgical intervention (PTx) and newer therapeutic options offer alternatives for refractory or advanced renal HPT.